×
For best experience we recommend to activate Javascript in your browser.
CTLA4 antibody (N-Term)
CTLA4
Reactivity: Human
WB, IHC (p), EIA
Host: Rabbit
Polyclonal
unconjugated
Product Details anti-CTLA4 Antibody
(hide)
Target
See all CTLA4 Antibodies
CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
Binding Specificity
All epitopes for CTLA4 antibodies
AA 57-86, N-Term
Reactivity
All reactivities for CTLA4 antibodies
Human
Host
All hosts for CTLA4 antibodies
Rabbit
Clonality
All clonalities for CTLA4 antibodies
Polyclonal
Conjugate
All conjugates for CTLA4 antibodies
This CTLA4 antibody is un-conjugated
Application
All applications for CTLA4 antibodies
Western Blotting (WB), Immunohistochemistry (Paraffin-embedded Sections) (IHC (p)), Enzyme Immunoassay (EIA)
Specificity
This antibody recognizes Human CD152 / CTLA4 (N-term).
Purification
Affinity Chromatography on Protein A
Immunogen
KLH conjugated synthetic peptide between 57-86 amino acids from the N-terminal region of Human CD152 / CTLA4. Genename: CTLA4
Isotype
Ig Fraction
Top Product
Discover our top product CTLA4 Primary Antibody
Alternatives
(show)
Application Details
(hide)
Application Notes
Optimal working dilution should be determined by the investigator.
Restrictions
For Research Use only
Handling
(hide)
Format
Liquid
Concentration
0.25 mg/mL
Buffer
PBS, 0.09 % Sodium Azide
Preservative
Sodium azide
Precaution of Use
This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Handling Advice
Avoid repeated freezing and thawing.
Storage
4 °C/-20 °C
Storage Comment
Store undiluted at 2-8 °C for one month or (in aliquots) at -20 °C for longer.
References for anti-CTLA4 antibody (ABIN951196)
(hide)
Karpathiou, Chauleur, Hathroubi, Habougit, Peoch : "Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease. " in: Cancer immunology, immunotherapy : CII , Vol. 67 , Issue 8 , pp. 1297-1303 , (2018 ) (PubMed ).
Karpathiou, Casteillo, Giroult, Forest, Fournel, Monaya, Froudarakis, Dumollard, Prades, Peoch : "Prognostic impact of immune microenvironment in laryngeal and pharyngeal squamous cell carcinoma: Immune cell subtypes, immuno-suppressive pathways and clinicopathologic characteristics. " in: Oncotarget , Vol. 8 , Issue 12 , pp. 19310-19322 , (2017 ) (PubMed ).
Target Details for CTLA4
(hide)
Target
CTLA4
(Cytotoxic T-Lymphocyte-Associated Protein 4 (CTLA4))
Alternative Name
CD152 / CTLA4 (CTLA4 Products )
Background
CTLA4 is a member of the immunoglobulin superfamily and encodes a protein which transmits an inhibitory signal to T cells. The protein contains a V domain, a transmembrane domain, and a cytoplasmic tail. Alternate transcriptional splice variants, encoding different isoforms, have been characterized. The membrane-bound isoform functions as a homodimer interconnected by a disulfide bond, while the soluble isoform functions as a monomer. Mutations in this gene have been associated with insulin-dependent diabetes mellitus, Graves disease, Hashimoto thyroiditis, celiac disease, systemic lupus erythematosus, thyroid-associated orbitopathy, and other autoimmune diseases.Synonyms: CTLA-4, Cytotoxic T-lymphocyte protein 4, Cytotoxic T-lymphocyte-associated antigen 4
Molecular Weight
24656 Da
Gene ID
1493
NCBI Accession
NP_001032720
Pathways
Cancer Immune Checkpoints
Recently viewed
(hide)